The coil-assisted flow diverters market is a part from the neurovascular devices which consists of products used for managing a complex intracranial aneurysm by diverting blood flow while promoting endothelialisation. They reduce flow stasis and encourage progressive thrombosis of the aneurysm while bringing decreased coils, which makes them a feasible minimally invasive option for treating wide-neck and bifurcation aneurysms.
In 2025, the global coil-assisted flow diverters market is projected to reach approximately USD 353.7 million, with expectations to grow to around USD 702.4 million by 2035, reflecting a compound annual growth rate (CAGR) of 7.1% during the forecast period.
The growth in the cerebral aneurysm treatment devices market is primarily driven by the increasing prevalence of cerebral aneurysms, the increasing preference for endovascular treatment over open surgery, and the technological advancements in the neurointerventional devices.
The market growth is attributed to the increasing geriatric population, rising preference for image-guided therapies, and increasing investment in neurovascular R&D. This projected CAGR indicates the growing integration of next-generation neurovascular products, rising need for minimally invasive procedures, and ongoing multicentre clinical trials evaluating the safety/effectiveness of advanced flow-diversion technologies.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 353.7 Million |
| Projected Market Size in 2035 | USD 702.4 Million |
| CAGR (2025 to 2035) | 7.1% |
Explore FMI!
Book a free demo
North America is driven by the high incidence of brain aneurysms in the region, whereas the presence of advanced healthcare infrastructure and major medical device players also support the growth of the market in North America. The adoption of neurovascular devices stands strong in both the United States and Canada due to the ability of trained neurointerventional specialists and the rising number of patients preferring minimally invasive treatment methods. Furthermore, the market is supported by the FDA approvals in innovative flow-diverting stents and upscaling investments in neurovascular research.
Europe holds a significant share of the market, and, as the largest share of neurovascular treatment advancements, Germany, France, and the United Kingdom follow in that order. National regulatory bodies alongside the EMA approve new neurointerventional devices, facilitating the rapid dissemination of coil-assisted flow diverters. Growing awareness of stroke prevention, government efforts for the early detection of aneurysms, and increasing collaborations in neurovascular research also support market growth.
The coil-assisted flow diverters market in the Asia-Pacific region is expected to grow at the fastest rate due to improving healthcare infrastructure, increasing medical tourism, and growing disposable income in countries such as China, India, and Japan. Increasing Healthcare Expenditure on Advanced Medical Technologies Supporting Market Demand: The growing caseload of cerebrovascular disease coupled with government investment in advanced medical technologies is driving the market demand. Moreover, increasing partnerships between international neurovascular enterprises and regional healthcare providers are propelling the market growth.
Challenges
High Cost and Limited Access to Advanced Neurovascular Treatment
The high cost of flow-diverting stents and neurovascular intervention procedures poses challenges to the Coil Assisted Flow Diverters market. While coil-assist flow-diverters have shown promising results, the high cost of such devices limits their accessibility, especially for developing regions which often lack specialized neurosurgeons and advanced interventional neuroradiology (INR) facilities, thus narrowing the clinical practical application of coil assist flow diverter for aneurysm treatment. Moreover, stringent regulatory approvals and lengthy clinical trial timelines do not favour market penetration.
Opportunity
Advancements in Minimally Invasive Neurovascular Devices and AI-Based Imaging
As the number of cerebral aneurysms and stroke cases continues to rise, there is significant demand for minimally invasive neurovascular treatment systems. Improved next-generation flow diverters featuring bioactive coatings, braided national scaffolding, and artificial intelligence-based imaging guidance are leading to better precision, safety, and long-term occlusion preservation of the aneurysm.
Flow diverters also continue to gain traction for treatment of complex aneurysms (e.g., large and wide-neck intracranial aneurysms) during the 2020-product approval to 2024-market access period. But high procedural costs, limited operator experience, and uncertainty regarding long-term thrombotic risk inhibited widespread adoption. The market was controlled by established companies such as Medtronic, Stryker, and MicroVention, which focused on gradual innovations in stent flexibility and endothelialisation-inducing coatings.
The flow diverter market is anticipated to transition toward bioresorbable flow diverters, procedures guided by AI, and combined therapies in addition to drug-eluting technologies by 2025 to 2035. Novel 3D-printed patient-specific flow diverters and robotic-assisted neurovascular interventions would transform the treatment outcomes in patients suffering from these cerebrovascular pathologies, allowing greater safety and cost-effectiveness during the procedure of coiling-assisted flow diverters in integrated current and emerging markets.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Compliance with FDA and CE mark regulations for neurovascular stents |
| Technology Innovations | Introduction of braided national flow diverters with improved flexibility |
| Market Adoption | Growth in intracranial aneurysm treatment using flow diverters |
| Treatment Efficiency | Early concerns over thrombosis risks and incomplete aneurysm occlusion |
| Market Competition | Dominated by major neurovascular device manufacturers (Medtronic, Stryker, MicroVention, Terumo) |
| Healthcare Accessibility | Limited availability in developing regions due to cost and infrastructure challenges |
| Sustainability & Material Science | Use of metal-based permanent flow diverters |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Stricter regulatory oversight on long-term safety, thrombosis prevention, and bioresorbable technologies |
| Technology Innovations | Advancements in bioresorbable flow diverters, AI-guided stent placement, and drug-eluting flow diverters |
| Market Adoption | Expansion into wider aneurysm types, stroke prevention, and personalized 3D-printed flow diverters |
| Treatment Efficiency | Next-gen bioactive coatings and endothelial-promoting materials for enhanced healing |
| Market Competition | Entry of biotech firms specializing in bioresorbable and AI-assisted neurovascular solutions |
| Healthcare Accessibility | Increased access with cost-effective flow diverters and robotic-assisted procedures |
| Sustainability & Material Science | Large-scale adoption of bioresorbable, polymer-based flow diverters with enhanced biocompatibility |
United States coil assisted flow diverters market is projected to grow at an impressive rate during the forecast period, due to rising incidence of intracranial aneurysms and growing acceptance of minimally invasive neurovascular procedures. Rapid growth is also driven by the availability of sophisticated healthcare infrastructure and heavy expenditure on neurointerventional technologies.
But continued innovations in stent-assisted embolization and increasing adoption of flow diverters as opposed to standard coiling practices are likely to bolster market growth. Growing adoption in the U.S. is also being supported by the FDA’s approval of new coil-assisted flow diverting devices and increased clinical research in neurovascular treatment options.
Increasing numbers of neurovascular surgeons and specialized stroke treatment centers nationwide are also facilitating broad utilization of coil-assisted flow diverters in complex aneurysm treatment.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 7.5% |
The UK coil assisted flow diverters market is driven by the rising cases of neurovascular disease and the development of minimally invasive endovascular procedures. National Health Service (NHS) is backing the progressive adoption of innovative technologies for aneurysm treatment, too, thus, propelling growth in this market.
Many of the leading biotechnology companies and universities are also continuously honing the technology of flow diverters and are ensuring that novel devices are developed optimally as clinical-grade products. The rising focus on early diagnosis and treatment of cerebrovascular disorders is also fueling the market growth.
Increasing government initiatives improving the neurovascular healthcare services along with enabling rapid access to advanced treatment options are propelling market growth and expected to have a positive influence on Neurovascular Device Market.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 7.0% |
The European Union (EU) coil assisted flow diverters market is one of the fastest-growing markets among the world market and will remain in the same direction over the forecast period due to continuous regulatory developments, the growing geriatric population, and constantly increasing cases of intracranial aneurysms. It bolsters the growth of the market owing to the high market interest among neuroscience practitioners, fostered by the European Medicines Agency (EMA) on the adoption of advanced neurovascular devices.
Germany, France, and Italy form vital markets backed by strong neurovascular research programs with high adoption rates of coil-assisted flow diverters in stroke treatment centers. The rising number of specialty care hospitals for neurology and the rising demand for endovascular aneurysm treatment demand is another factor fuelling the overall demand.
Moreover, the increasing availability of government healthcare funding for stroke prevention and neurovascular treatment programs is also driving the market growth.
| Country | CAGR (2025 to 2035) |
|---|---|
| EU | 6.9% |
Increasing prevalence of neurovascular disorders has led to the growth of Japan Coil Assisted Flow Diverters market, and the country has also witnessed advancements in neurovascular imaging along with minimally invasive surgical techniques. The growing prevalence of cerebrovascular diseases is another factor driving market growth, particularly as Japan has a relatively large aging population.
Japan’s national healthcare system has made a strong focus on early diagnosis and treatment of neurovascular diseases, thus the adoption of coil-assisted flow diverters is aggressively being pursued. Moreover, domestic companies in the field of medical devices and research institutes are actively developing new technologies for neurovascular treatment.
The growing number of market players and the interest of regulatory authorities to support novel endovascular devices in particular, and the growing number of neurointerventional specialists in Japan are additional driving forces.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 7.3% |
Demand for coil assisted flow diverters in South Korea is stimulated by increasing investment in the neurovascular healthcare infrastructure and the number of stroke treatment centers in South Korea. A focus on technology development in interventional neurology in the country is propelling the market growth.
Government initiatives that focus on improving stroke management are driving the uptake of advanced flow diverter devices, which are anticipated to significantly reduce the burden of cerebrovascular diseases. Rising collaborations between South Korean hospitals and international medical device companies are contributing to innovation in the technologies used to treat aneurysms.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 7.1% |
As medical technologies develop, the accuracy of endovascular treatments increases and boosts growth of coil assisted flow diverters market. Wide-neck aneurysms represent a complex neurovascular problem that is challenging to treat, requiring coil assisted flow diverters. Such devices are used effectively at each site (neurosurgeons and interventional radiologists) as they provide better aneurysms occlusion at the same time preserving branch vessel patency.
The combination of bioresorbable polymers with next-generation stent designs has made it even more effective, accelerating endothelialisation and securing long-term stability.
These feature-rich devices are beneficial, but cost restrictions and technical complexity inhibit widespread adoption in developed regions. On the other hand, growing investments towards healthcare and increasing neurovascular centers globally are anticipated to boost the growth of the wide-neck bifurcation aneurysms treatment market segment and thereby maintaining a market presence.
The bifurcation aneurysms segment has gained significant traction in recent years as coil assisted flow diverters have established themselves as the standard therapy for the treatment of aneurysms located at vascular branch points. Aneurysms, particularly if endovascular coiled, pose specific obstacles to approach because of the intricate hemodynamic and coil migration risks. Unlike traditional coiling, coil assisted flow diverters induce intravascular thrombosis while causing little interference to the normal blood flow of adjacent arteries.
With the evolution of technology has arisen flexible, braided flow diverters that allow better navigation and placement. Moreover, the growth in demand has been accelerated by the rising preference for minimally invasive procedures, with patients and healthcare professionals looking for alternatives to open surgery that entails shorter recovery periods and lesser risk associated with the procedures.
Bifurcation aneurysms pose additional challenges to onerous treatment options due to various anatomical considerations, but new research and clinical trials are perfecting device design for improved versatility and adaptability. Ongoing refinement of new materials and bioengineered coatings further entrains improved device compatibility in affirming a coil assisted flow diverter sauteur over unruptured bifurcation and complicated aneurysms.
Hospitals have the highest burden of the coil assisted flow diverters market, due to their presence of well-developed neurovascular departments and well trained neurosurgeons in the facilities. Hospitals, as tertiary care centers, manage patients with aneurysms requiring complex imaging, multidisciplinary approaches, and advanced intervention methods. In the clinical environment, the use of coil assisted flow diverters for the endovascular management of intracranial aneurysms has also been propelled by the availability of state-of-the-art hybrid operating theatres and catheterization laboratories.
The growing availability of stroke centers and neurovascular units has increased access to these procedures, therefore improving outcomes and success rates as provided by large cohort studies around the world. Early detection of stroke has been supported by the government, which has allocated funds for stroke prevention interventions, promoting hospital-based neurovascular unit (NVU) care and supporting hospitals as prominent distributors in the coil assisted flow diversion segment.
While reimbursement policies and high procedural costs pose significant hurdles, the market adoption is still significantly led by hospitals as they have the capability to integrate advanced medical technologies along with comprehensive post-procedural care. The hospital segment is on the rise, due to increasing incidences of cerebrovascular disorders and the increasing availability of fellowships in endovascular surgeries.
With the evolution in neurovascular procedures leading to minimally invasive, outpatient, or day-care setting treatments, clinics are becoming crucial distribution channels for coil assisted flow diverters. High-quality interventions have also been provided at specialized neurovascular clinics and ambulatory care centers to improve patient access to coil assisted flow diverters outside of traditional hospital settings in an ambulatory setting. These clinics are a cost-saving alternative for patients seeking prompt treatment without extended hospital stays.
An increasing number of centers performing interventional neuroradiology has favored the market development of coil assisted flow diverters for the clinical settings. These facilities provide specialized aneurysm screening, diagnosis, and treatment services and serve an expanding patient population with challenging vascular diseases. Decentralization of neurovascular care from large academic medical centers to privately funded specialty clinics has enhanced efficiency with decreased wait times and procedural delay.
Although clinics do not possess all resources of a hospital-based neurosurgical facility, their capability for selective interventions and individualized patient management further strengthens their involvement in coil assisted flow diverter distribution. Rising adoption of digital health solutions and telemedicine integration into neurovascular clinics are expected to propel market segment growth and sustain market penetration.
The collapsible sleeve containers are a form of bulk packaging containers, these containers are primarily designed for the conveyance and storage of bulk materials in motor vehicles. Teff bags are popular with supply chain projects and also sustainability packaging efforts as they provide improved durability, aid in storage, and reduce shipping rates. The growing trend of adopting returnable packaging solutions to reduce waste and carbon footprint also drives the market as a significant aspect.
Market Share Analysis by Key Players
| Company/Organization Name | Estimated Market Share (%) |
|---|---|
| Schoeller Allibert | 18-22% |
| ORBIS Corporation (Menasha Corporation) | 14-18% |
| DS Smith Plc | 12-16% |
| IPL Plastics | 10-14% |
| Rehrig Pacific Company | 8-12% |
| Others | 26-32% |
| Company/Organization Name | Key Offerings/Activities |
|---|---|
| Schoeller Allibert | Develops heavy-duty collapsible sleeve containers for automotive, agriculture, and logistics industries. |
| ORBIS Corporation | Specializes in returnable sleeve containers with foldable, lightweight designs for supply chain efficiency. |
| DS Smith Plc | Provides fiber-based and plastic collapsible sleeve solutions with a focus on sustainable packaging. |
| IPL Plastics | Manufactures customized collapsible bulk containers for retail and industrial applications. |
| Rehrig Pacific Company | Offers high-durability collapsible sleeve containers for distribution and warehousing logistics. |
Key Market Insights
Schoeller Allibert (18-22%)
Schoeller Allibert leads the market with heavy-duty, reusable collapsible sleeve containers designed for efficient storage and transport. The company focuses on automotive, industrial, and agricultural applications, integrating high-strength materials for long-term use.
ORBIS Corporation (Menasha Corporation) (14-18%)
ORBIS is a key player in returnable and reusable packaging solutions, providing lightweight, easy-to-handle collapsible sleeve containers. The company targets retail, food & beverage, and warehouse automation industries.
DS Smith Plc (12-16%)
DS Smith specializes in fiber-based and plastic collapsible sleeve containers, offering sustainable and recyclable solutions for e-commerce, logistics, and FMCG (fast-moving consumer goods) sectors.
IPL Plastics (10-14%)
IPL Plastics manufactures customized, collapsible bulk containers tailored to specific industrial, retail, and food supply chain needs. The company is investing in innovative designs for enhanced stack ability and cost reduction.
Rehrig Pacific Company (8-12%)
Rehrig Pacific provides high-durability collapsible sleeve containers for distribution and logistics applications, with a focus on warehouse automation and material handling.
Other Key Players (26-32% Combined)
The overall market size for coil assisted flow diverters market was USD 353.7 million in 2025.
The coil assisted flow diverters market is expected to reach USD 702.4 million in 2035.
The growth of the coil assisted flow diverters market will be driven by increasing prevalence of intracranial aneurysms, advancements in minimally invasive neurovascular treatments, and rising adoption of innovative stent-based technologies for effective blood flow management.
The top 5 countries which drives the development of coil assisted flow diverters market are USA, European Union, Japan, South Korea and UK.
Wide-neck bifurcation aneurysms to command significant share over the assessment period.
Erythema Treatment Market Insights - Size, Growth & Forecast 2025 to 2035
Dystrophic Epidermolysis Bullosa Management Market - Trends & Outlook 2025 to 2035
Drug Eruptions Treatment Market - Innovations & Future Outlook 2025 to 2035
Diamond-Blackfan Anemia (DBA) Syndrome Therapeutics Market - Growth & Innovations 2025 to 2035
Diabetic Retinopathy Market Analysis - Size, Share & Forecast 2025 to 2035
eClinical Solutions and Software Market Insights - Trends & Forecast 2025 to 2035
Coil Assisted Flow Diverters Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
